Concepedia

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer

Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr Chłosta, José Manuel Cervera Grau, Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel,

European Urology · 2013 · 79 citations · 7 references

DOIFull text

Open access

Concepts

References

7

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

, , +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

, , +13

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function

Ronald C. Serlin, Tito R. Mendoza, Yoshio Nakamura et al. · Pain · 1995 · 1.5K citations

, , +13

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

Rosa A. Carrasco, Nancy B. Stamm, Eric G. Marcusson et al. · Molecular Cancer Therapeutics · 2011 · 126 citations · Full text

, , +17

Expression of the Survivin Gene in Prostate Cancer: Correlation With Clinicopathological Characteristics, Proliferative Activity and Apoptosis

Hirofumi Kishi, Mikio Igawa, Nobuyuki Kikuno et al. · The Journal of Urology · 2004 · 99 citations

, , +14